RAB0630
Human NPPB / Natriuretic Peptides B ELISA Kit
for serum, plasma, cell culture supernatants and urine
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41116158
NACRES:
NA.32
Recommended Products
species reactivity
human
packaging
kit of 96 wells (12 strips x 8 wells)
technique(s)
ELISA: suitable
input
sample type urine
sample type cell culture supernatant(s)
sample type plasma
sample type serum
assay range
inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 14 pg/mL
standard curve range: 15.63-1000 pg/mL
detection method
colorimetric
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... NPPB(4879)
General description
The NPPB ELISA kit provides for the Quantitative measurement of Natriuretic Peptides B in Cell Culture Supernatants, Plasma and Serum.
Application
For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Other Notes
A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.
Please type the word sample in the text box provided for lot number.
Kit Components Also Available Separately
Product No.
Description
SDS
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Met. Corr. 1
Storage Class Code
8A - Combustible corrosive hazardous materials
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jingfa Zhu et al.
Cell cycle (Georgetown, Tex.), 18(16), 1948-1964 (2019-06-27)
Recently, MicroRNA-98 (miR-98) works as a biomarker in some diseases, such as lung cancer, Schizophrenia, and breast cancer, but there still lack of studies on the function of miR-98 during sepsis. Thus, our study is conducted to figure out the
Mudit Mishra et al.
Scientific reports, 10(1), 8382-8382 (2020-05-21)
Therapeutic interventions with proven efficacy in heart failure with reduced ejection fraction (HFrEF) have been unsuccessful in heart failure with preserved ejection fraction (HFpEF). The modifiable risk factor with the greatest impact on the development of HFpEF is hypertension. The
Jeppe Lerche la Cour et al.
The Journal of clinical endocrinology and metabolism, 104(4), 1232-1238 (2018-11-02)
Thyroid hormone metabolites might affect the heart. The endogenous aminergic metabolite 3-iodothyronamine (T1am) reduces left ventricular ejection fraction (LVEF) in rodents. To investigate concentration of T1am and its association with LVEF and biomarkers of heart function in patients with chronic
Mariann Gyöngyösi et al.
Cardiovascular research, 116(5), 970-982 (2019-07-28)
The clinical application of doxorubicin (DOX) is severely compromised by its cardiotoxic effects, which limit the therapeutic index and the cumulative dose. Liposomal encapsulation of DOX (Myocet®) provides a certain protective effect against cardiotoxicity by reducing myocardial drug accumulation. We
Yusuke Ito et al.
FEBS open bio, 8(5), 799-816 (2018-05-11)
5-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) have beneficial effects in patients with heart failure (HF), regardless of serum cholesterol levels. However, their synergic effects with angiotensin II receptor blocker (ARB) remain to be established. We assessed the existence and potential underlying mechanisms
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service